REG - N4 Pharma PLC - Placing to raise £1million and Broker Offer

N4 PharmaAnnouncement

18/11/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221118:nRSR8278Ga&default-theme=true

RNS Number : 8278G  N4 Pharma PLC  18 November 2022

18 November 2022

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulations
(EU) No. 596/2014 which has been incorporated into UK law by the European
Union (Withdrawal) Act 2018.  Upon the publication of this announcement via
Regulatory Information Service, this inside information is now considered to
be in the public domain.

 

 

N4 Pharma plc

 

("N4 Pharma" or the "Company")

 

Placing to raise £1million

 

Broker Offer

 

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing
Nuvec®, a novel delivery system for cancer treatments and vaccines, is
pleased to announce that it has raised £1 million (before expenses) through a
placing of 50,000,000 new ordinary shares of 0.4p each in the Company (the
"Placing Shares") at an issue price of 2p ("Issue Price") per Placing Share
(the "Placing").  The Placing was undertaken by Turner Pope Investments (TPI)
Limited ("TPI").

 

The net proceeds of the Placing will be used to progress the Company's
development work relating to the loading of SiRNA onto Nuvec®, including to
commit to doing in-vivo studies and also to explore acquisition opportunities.

 

Nigel Theobald, Chief Executive of N4 Pharma, commented: "The additional
funding raised provides sufficient working capital for our Nuvec® program
into 2024 and will enable us to do more in vivo development work on double
loaded SiRNA on Nuvec® and begin business development on this opportunity.
 Alongside this, we will undertake further research to support our patent
application on the use of Nuvec® to improve the efficiency of viral vectors
and start business development activities in this area.

 

"This funding will also give us more scope to continue to look for additional
asset opportunities alongside Nuvec."

 

Broker Offer

 

To provide shareholders and other investors who did not initially participate
in the Placing the opportunity to invest in the Company, under the Placing
Agreement, TPI will launch a broker offer ("Broker Offer") under which TPI
will, as agent for the Company, invite subscriptions for additional new
ordinary shares ("Broker Offer Shares") with an initial expected value of
£0.25 million at the Issue Price.  The Broker Offer may be extended, with
the express agreement of the Company, to £1.0 million in the event the Broker
Offer is oversubscribed.  The Broker Offer opens immediately following this
announcement and will close at 4.30 p.m. on 21 November 2022.

 

As far as is practical, participation in the Broker Offer will be prioritised
for qualifying shareholders (direct or indirect) on the Company's share
register at the close of business on 17 November 2022 ("Existing
Shareholders").  If the maximum subscription under the Broker Offer is taken
up, it will raise an additional £1 million, before expenses, for the Company.

 

To subscribe for Broker Offer Shares, Existing Shareholders or other
interested parties who wish to register their interest in participating in the
Broker Offer should click on the following link : N4 Pharma Broker Offer
(https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fforms.office.com%2Fr%2FT1NwuLTc7b&data=05%7C01%7CAndy.Thacker%40TurnerPope.com%7C4f2cd6e21a26487666d108dac896f44f%7Cff82bd738fe84a38a86994e58a240e55%7C0%7C0%7C638042847908576330%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=ZTwQMELPoVJRhmFZwYB6Q4ViTnJPTGPnKcyMqUTybQk%3D&reserved=0)

 

A further announcement will be made following the end of the period during
which the Broker Offer is open.  If the Broker Offer is not fully subscribed
by 4.30 p.m. on 21 November 2022, orders from eligible investors will be
satisfied in full, and the balance of the Broker Offer shall lapse.

 

Broker Warrants

 

As part of its fee, TPI will be issued with warrants ("Broker Warrants") to
subscribe for new ordinary shares exercisable at the Issue Price, such number
of warrants that would be equivalent to 6 (six) per cent. of the gross
aggregate value of funds raised in the Placing and Broker Offer.  The Broker
Warrants have a term of 36 months from the date of admission of the Broker
Offer Shares to trading on AIM and are being issued under the Company's
existing share authorities.

 

Application for Admission

 

The Placing has been conducted utilising the Company's existing share
authorities.  Application has been made for the Placing Shares to be admitted
to trading on AIM ("Admission") and it is expected that Admission will take
place at 8.00 a.m. on or around 24 November 2022.  Once issued, the Placing
Shares will rank pari passu with the Company's existing ordinary shares.

 

A further announcement will be made regarding the admission to trading of the
Broker Offer Shares to be issued pursuant to the Broker Offer which is also
being conducted utilising the Company's existing share authorities.

 

Total Voting Rights

 

Following Admission of the Placing shares, the enlarged issued share capital
of the Company will comprise 231,080,349 ordinary shares of 0.4 pence each.
The Company does not hold any ordinary shares in treasury.  Consequently,
231,080,349 is the figure which may be used by shareholders as the denominator
for the calculation by which they will determine if they are required to
notify their interest in, or a change to their interest in, the Company under
the FCA's Disclosure and Transparency Rules. A separate notification will be
made following closure of the Broker Offer.

 

 

Enquiries:

 

 N4 Pharma plc
 Nigel Theobald, CEO                                         Via IFC Advisory
 Luke Cairns, Executive Director

 SP Angel Corporate Finance LLP                              Tel: +44(0)20 3470 0470
 Nominated Adviser and Joint Broker
 Matthew Johnson/Caroline Rowe (Corporate Finance)
 Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)

 Turner Pope Investments (TPI) Limited                       Tel: +44(0)20 3657 0050
 Joint Broker
 Andy Thacker

 James Pope

 IFC Advisory Ltd                                            Tel: +44(0)20 3934 6630
 Financial PR
 Graham Herring
 Zach Cohen

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery
system for cancer and vaccine treatments using its unique silica nanoparticle
delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel
antigens for cancer and vaccine treatments to use Nuvec® as the delivery
vehicle to get their antigen into cells to express the protein needed for the
required immunity.  As these products progress through preclinical and
clinical programs, N4 Pharma will seek to receive upfront payments, milestone
payments and ultimately royalty payments once products reach the market.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEBRBDBUXBDGDR